Updated:
Jiangsu Yuyue Medical Equipment & Supply
Jiangsu Yuyue Medical Equipment & Supply was established in 1998 in Danyang, Jiangsu, by Wu Guangming to make blood-pressure monitors and other home-care...
Jiangsu Yuyue Medical Equipment & Supply
Jiangsu Yuyue Medical Equipment & Supply was established in 1998 in Danyang, Jiangsu, by Wu Guangming to make blood-pressure monitors and other home-care devices affordable across China's emerging consumer-healthcare market. The company listed on the Shenzhen Stock Exchange (SZ: 002223) and grew into one of China's largest domestic medical-device manufacturers, with a product catalog spanning oxygen concentrators, nebulizers, and pulse oximeters. The founding family retains control through Wu Qun, who succeeded his father as chairman and CEO, while the broader board includes figures from Chinese academia and state-linked healthcare networks. The firm deploys capital through two lanes: in-house R&D and manufacturing scale-ups within its core respiratory and chronic-disease categories, and external minority investments in healthcare startups via its strategic investment arm. Asset classes include private equity, venture capital, and direct operating assets. It co-invests alongside technology conglomerates and venture funds — Tencent participated in a round for Yuwell's internet-health subsidiary Xunjie Medical, and Sequoia Capital China has partnered on healthcare deals. Geographically, Yuwell sells into Southeast Asia, South Asia, the Middle East, and Africa through a network of distributors, supplementing its dominant position inside China. Beyond its Danyang production campus, Yuwell operates commercial headquarters in Nanjing and Shanghai and maintains global R&D centers. The group controls a private jet for executive travel and holds the chairmanship of the Chinese Medical Equipment Industry Association, signaling policy-level influence. In September 2023, the company reported a restructuring of its hypertension and respiratory product lines under a single chronic-disease management unit, reflecting a pivot toward integrated care bundles rather than standalone hardware sales. The firm's structural differentiator is vertical integration between a state-listed manufacturing flow and a venture book that feeds on the manufacturing arm's distributor relationships. Rather than competing as a pure financial investor, Yuwell offers portfolio companies accelerated regulatory navigation through CFDA/NMPA processes and immediate shelf space inside China's tier-2 and tier-3 hospital procurement systems — a bundling of capital and commercialization that conventional VC funds cannot replicate.
General information
Firm type
Corporate Investor
Year founded
1998
Location
Region
Asia
Country
China
City
Danyang
Corporate office
No. 1 Baisheng Road, Development Zone, Danyang, Jiangsu, China
Additional offices
Nanjing, Jiangsu, China · Shanghai, China
Principals
Wu Qun
Chairman and CEO
Wu Guangming
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Yuwell?
Investment decisions ultimately flow through Chairman and CEO Wu Qun, son of founder Wu Guangming. The firm does not disclose a separate CIO or investment committee for corporate venture activity, suggesting capital allocation is managed through the parent company's executive leadership.
Does Yuwell operate a dedicated venture fund?
No dedicated venture fund is publicly disclosed. Yuwell invests via its corporate balance sheet and operates Xunjie Medical, a subsidiary focused on smart respiratory devices, which received strategic investment from Tencent. All known deployment is direct rather than through a separate limited partnership structure.
What healthcare subsectors does Yuwell target for investment?
Yuwell concentrates on homecare medtech, including respiratory care and chronic disease management devices. The firm also backs digital health ventures that connect diagnostic hardware to telemedicine platforms, reflecting the parent company's existing expertise in oxygen concentrators and blood pressure monitors.
Which co-investors participate in Yuwell's venture deals?
Tencent Holdings and Sequoia Capital China are the two named co-investors in prior Yuwell-related healthcare investment rounds, per public record. The firm's industry association chairmanship also suggests deep state-affiliated capital links, though these are not formally disclosed as co-investors.
How is Yuwell related to Xunjie Medical?
Xunjie Medical is a subsidiary of Yuwell focused on internet-connected respiratory care devices. Tencent became a strategic investor in Xunjie Medical, making it a key vehicle for Yuwell's digital health push while the parent company retains operational control.
Does Yuwell maintain active philanthropic programs?
Yes. Yuwell Medical CSR Initiatives handles the family's corporate social responsibility programs. The firm has directed medical device donations and pollution-related health support efforts in China, though it does not disclose a separate foundation entity.
What is Yuwell's approach to manufacturing versus investment?
Yuwell treats venture investment as an extension of its manufacturing ecosystem, not a standalone financial activity. Capital deployment often takes the form of direct subsidiary creation or strategic enterprise investment that simultaneously secures technology access, supply-chain coverage, and channel expansion for core device product lines.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: